How do you build a vertical SaaS for veterinary clinics (Cornerstone / ezyVet) go-to-market motion in 2027?

The go-to-market motion in one picture

A vertical SaaS motion for veterinary clinics is not one funnel—it is three overlapping funnels stitched to a single proof artifact. The independent single-location hospital runs a fast, inside-sales-driven cycle of 30 to 90 days, where the buyer is often the owner and the signature is one conversation away. The mid-market hospital group of roughly 5 to 99 locations runs a field-plus-champion cycle of three to nine months, gated by a regional VP and a corporate-IT reviewer. The enterprise consolidator—Mars Veterinary Health (Banfield, BluePearl, VCA), National Veterinary Associates, Thrive Pet Healthcare, PetVet Care Centers, Southern Veterinary Partners—runs a corporate-IT cycle of 12 to 24 months with a formal security review and a phased migration plan.

What unifies all three is the artifact that earns the vote: a live 60-day pilot at one hospital, running your product side-by-side with the incumbent, measuring lab-result round-trip accuracy, controlled-substance audit readiness, appointment no-show rate, and the attach of boarding, grooming, and retail—lines many general-practice hospitals lean on for 20 to 40 percent of top-line revenue. The pilot is the fulcrum: everything upstream exists to earn it, and everything downstream exists to expand it.

The trigger events that open these cycles are specific and recurring: a Cornerstone maintenance-fee increase, a looming DEA inventory audit, a merger that forces platform consolidation, or a new hospital opening that needs software on day one. A modern go-to-market team instruments for those triggers—monitoring trade media, distributor chatter, and hiring signals—rather than spraying cold outreach, because the veterinary buyer researches on trade publications and peer forums for months before a rep ever gets a callback.

The picture matters because the common failure is treating this vertical like generic B2B SaaS. It is not. The clinical workflow, the pharmacy compliance load, and the lab-vendor gravity of IDEXX shape every stage. A motion that ignores them looks healthy on the pipeline dashboard and then dies silently at the lead-vet-tech demo, where the person who will actually type into the system every shift decides whether your workflow helps or hurts patient care.

Who owns what across the revenue org

Mapping the buying committee to your own revenue org is the single highest-leverage design decision in a veterinary vertical. In practices with two or more veterinarians, a PMS purchase touches four to five stakeholders, and each one can veto. Selling only to the owner is the most common reason deals stall in month two—the owner says yes, then the lead tech quietly says no.

The DVM-owner or medical director owns the product decision and the signature. They care about clinical quality, staff retention, and whether a switch will disrupt patient care during a busy season. Your founder-led seller or a senior AE with genuine veterinary credibility owns this relationship; ROI and staff-retention arguments land here directly because the owner also holds the P&L. The practice manager or hospital administrator owns daily operations—scheduling, boarding, grooming, retail, invoicing, and staff hours—and feels the pain of a clunky system every single day. Your AE plus a solutions consultant who once worked inside a hospital owns this seat, and the practice manager is usually your internal champion.

The lead vet tech or hospital manager owns clinical workflow: treatment sheets, anesthesia records, the whiteboard, and controlled-substance handling that must survive a DEA audit. This is the seat that kills deals silently, so your implementation lead and a clinically fluent solutions engineer must win it live in the demo, not in a slide. The hospital-group IT director or regional VP appears only in mid-market and enterprise deals and owns multi-location rollout, integration testing, and data migration; your field AE plus a dedicated integration engineer own it. Finally, the inventory and pharmacy lead owns DEA Form 222 records, biennial controlled-substance inventory, vaccine stock, and distributor integration with Patterson Veterinary, Henry Schein Animal Health, MWI, and Covetrus. Your product and partner teams own this seat by shipping a real controlled-substance ledger—not a bolt-on and not a roadmap promise.

On the seller side, the clean division of labor is: founder or VP Sales for owner and economic conversations; AE plus solutions consultant for workflow and operations; an implementation and cutover lead for the pilot-to-go-live handoff; a partner manager for distributor and lab relationships; and a customer success manager who owns expansion revenue after the first hospital is stable for 90 days. When these mappings blur—an AE trying to sell the lead vet tech on ROI, or a CSM trying to run a DEA-compliance conversation—win rates fall measurably, because each seat wants to hear from someone who speaks its language.

Metrics, targets, and realistic ranges

The economics of a vertical veterinary PMS separate cleanly by tier, and setting targets to the wrong tier is how teams misread their own funnel and fire good reps for missing quotas that were never calibrated.

For single-location independents, expect annual contract value in the roughly $4,000 to $40,000 range, driven by a core subscription of about $179 to $649 per location per month, a per-veterinarian seat of $99 to $249, add-on modules (boarding, grooming, retail, telehealth, imaging) at $149 to $549 each, and a payments take-rate of 2.49 to 3.5 percent that becomes the largest long-term revenue line as transaction volume grows. Cycle length runs 30 to 90 days. For mid-market hospital groups, ACV lands in the $40,000 to $500,000 range over a three-to-nine-month cycle. For enterprise consolidators, platform-plus-per-location pricing pushes ACV into the hundreds of thousands to several million dollars, with a 12-to-24-month cycle and a separate annual platform fee for the largest groups.

Conversion and retention targets a healthy motion should hit: overall win rate of roughly 22 to 36 percent, climbing toward the low 40s on deals where a 60-day pilot actually ships—the pilot is the single biggest win-rate lever you control. Net revenue retention should sit at 104 to 120 percent, driven by new-hospital adds as groups acquire clinics, payments-volume growth, and module attach rather than seat-price increases. CAC payback loaded with payments and module revenue runs 6 to 16 months; subscription-only payback stretches to 18 to 30 months, which is why the payments and add-on attach is strategic, not incidental. Gross margin should land in the 60 to 78 percent band once hosting, support, and payment-processing costs are netted.

Pipeline-cost discipline matters at this scale. Expect $180 to $680 per inbound lead from trade-media and search channels, and $900 to $3,500 per outbound opportunity from inside and field sales in vet-dense metros. The channel mix that tends to work is roughly 30 percent inbound (DVM360, Today's Veterinary Practice, Veterinary Practice News, AAHA content, G2, Capterra, and community forums), 30 percent partner-led (distributors, AAHA accreditation, veterinary schools, and corporate-IT relationships), 25 percent outbound, 10 percent conference-driven (VMX and WVC together move a large share of mid-market pipeline), and 5 percent existing-customer multi-location expansion.

The metric to watch above all others is pilot-to-paid conversion. If pilots convert below 60 percent, the problem is almost never price—it is that the pilot failed to prove lab integration or controlled-substance compliance, the two capabilities clinical staff will not compromise on regardless of how attractive the price or the interface looks.

Where the motion breaks down

Four failure modes account for most losses, and each has a concrete counter you can build for.

IDEXX lab lock-in. IDEXX operates the majority of in-clinic reference and point-of-care lab equipment and also owns Cornerstone and the cloud product Neo, so practices running IDEXX analyzers feel a strong pull to stay on an IDEXX PMS. You do not out-incumbent IDEXX; you neutralize the lock-in by shipping certified, deep bidirectional integration to IDEXX analyzers plus parity integration to Antech (Mars) and other lab networks, so the practice keeps every analyzer it already owns. If your lab integration is shallow, the lead vet tech ends the pilot in week one and no discount will reopen it.

DEA controlled-substance audit risk. Veterinary hospitals dispense ketamine, buprenorphine, butorphanol, diazepam, phenobarbital, and similar scheduled drugs, and are subject to DEA Form 222 ordering, perpetual electronic logging, biennial inventory, and lost-stolen-broken reporting. A PMS without a native controlled-substance ledger fails the compliance seat outright. This is a build requirement, not a marketing claim—in the demo you show the audit report the hospital would hand a DEA investigator, not a roadmap slide describing one.

Corporate-IT and contract lock-in. Large hospital groups sit on multi-year contracts with Cornerstone, AVImark, or Vetspire, and their corporate IT teams own migration risk. Winning here requires a documented migration and integration-test plan, a multi-year ROI model, and a phased rollout that de-risks the first ten locations before the group commits the rest. Skipping the IT relationship and selling only the regional VP is a reliable way to lose in procurement, where the person who never saw your demo controls the final signature.

Boarding, grooming, and retail misfit. Because these lines can be a fifth to two-fifths of clinic revenue, a PMS that lacks native boarding, grooming, and retail modules forces the clinic to bolt on separate tools and stitch integrations, and that friction alone loses deals. Native modules—kennel calendars, grooming appointments, retail inventory tied to the same invoice—are table stakes for the general-practice and mixed-model hospital, even though a pure specialty or ER hospital may not need them. Reading which sub-vertical you are selling into, and matching the module set to it, prevents a mismatched demo that signals you do not understand the buyer.

A fifth, quieter failure is treating training and cutover as an afterthought. Data-migration errors, missed staff training, and a go-live during a busy season can turn a technically sound win into a churned logo within a quarter—which is exactly why the implementation lead is a first-five hire, not a scale hire.

How to sequence the build

Sequence the company the way you sequence the market: beachhead first, then adjacent tiers. Start with single-location independents in two or three vet-dense metros—Denver, Portland, and Austin are representative—using an inside SDR, a virtual demo, and a free 60-day trial, targeting a first wave of 80 to 120 logos to prove the pilot mechanics and generate reference customers. Only then expand to mid-market hospital groups, adding two or three field reps and a champion-based motion aimed at 15 to 30 group logos, where ACV steps up an order of magnitude. Enterprise consolidators come last, typically in year four or five, once you can hire ex-IDEXX, ex-Henry Schein, or ex-Covetrus field executives who carry corporate relationships and can survive a 12-to-24-month cycle.

Hiring follows the same arc. The first five hires are a founder-led or ex-Cornerstone/AVImark seller for credibility, a former practice manager or vet tech turned AE for daily-user fluency, an inside SDR for the fast independent cycle, an implementation and cutover lead who owns pilots and go-lives, and a lab-and-integration lead who owns IDEXX and Antech certifications. By ten hires, add two more inside reps, a field rep for group accounts, a distributor partner manager, an integration engineer covering lab, DEA, and payments, and a content marketer feeding the inbound engine. By twenty-five, layer in eight to twelve reps, a VP Sales, a VP Customer Success, four to six implementation engineers, an enterprise specialist, demand-gen and paid-search ownership, a RevOps analyst, and a security analyst—because a multi-tenant platform holding controlled-substance and payment data is a genuine breach target.

Run the whole thing on a fixed cadence: daily checks on lab-integration uptime and controlled-substance audit-trail health; weekly pipeline and cutover reviews with integration-certification burn-down; monthly payments take-rate, imaging attach, boarding-grooming attach, and NRR cohort analysis; quarterly hospital-group business reviews and expansion planning; and an annual conference-pipeline pull around VMX and WVC plus a security penetration test. That operating rhythm is what turns a promising vertical wedge into durable, expanding revenue instead of a one-hospital novelty.

Related questions

How is a veterinary PMS different from a human EHR go-to-market?

Veterinary buyers own the practice and the P&L, so ROI and staff-retention arguments land directly with the decision-maker—unlike hospital IT committees. The clinic also runs boarding, grooming, and retail revenue lines a human EHR never touches, and lab-vendor gravity from IDEXX shapes the deal far more than any single human-health lab relationship does.

Should you build payments in from day one?

Yes. Embedded payments at a 2.49 to 3.5 percent take-rate becomes the largest recurring revenue line as transaction volume grows, and it is what pulls CAC payback from 18–30 months down toward 6–16. Launching subscription-only and adding payments later leaves the most durable revenue on the table.

What sub-verticals are most underserved in 2027?

Equine ambulatory, mobile and housecall practice, exotic and avian medicine, emergency and specialty ER, shelter and low-cost spay-neuter clinics, and telemedicine remain thinly served by legacy Cornerstone-era tools. Modern cloud entrants wedge here because incumbents optimized for the general-practice small-animal hospital.

How long should the pilot run and where?

Sixty days at one hospital, side-by-side with the incumbent. That window is long enough to prove lab-result round-trips, a controlled-substance audit report, scheduling, and a clean data cutover, while short enough to keep the buying committee engaged. Shorter pilots fail to surface the workflow edge cases that actually decide the deal.

FAQ

What is the right opening price for a single-location independent? A subscription of roughly $249 to $399 per location per month, plus $99 to $179 per veterinarian, plus a 2.6 to 2.9 percent payments take-rate, with imaging or telehealth modules priced separately. Favor one-year terms over three-year contracts, because switchers moving off Cornerstone or AVImark resist long lock-ins after being burned once.

How do you compete against Cornerstone's large installed base and lab lock-in? You do not out-incumbent it. You out-cloud and out-workflow it: a cloud-native product with modern clinical workflow, native controlled-substance compliance, and certified IDEXX plus Antech lab parity reframes the choice as "legacy on-prem versus modern cloud" rather than a feature-by-feature bake-off you would lose on breadth.

What CAC payback should you target? Six to sixteen months when loaded with payments and module revenue. Subscription-only motions run 18 to 30 months, which is why embedding payments and driving add-on attach is a strategic requirement rather than an upsell nicety for a veterinary vertical with thin standalone subscription ACV.

What net revenue retention is realistic for veterinary PMS? 104 to 120 percent. Expansion comes from new-hospital adds as groups acquire clinics, growing payment volume, imaging and telehealth attach, and boarding-grooming-retail module adoption—not from raising per-seat prices, which erodes trust with owner-operators who watch every line item.

How do you handle multi-location expansion after the first win? Wait for the first hospital to run clean for about 90 days, then have the CSM trigger expansion with the DVM-owner, practice manager, and hospital-group IT together. Offer a multi-location discount, a dedicated rollout project manager, and a corporate dashboard so IT co-owns the rollout with you.

Do you need native boarding, grooming, and retail from launch? For general-practice and mixed-model hospitals, yes—those lines can be 20 to 40 percent of clinic revenue, and forcing a bolt-on integration loses deals. Pure specialty or ER hospitals may not need them, so match the module set to the sub-vertical you are actually selling into.

Sources

• American Veterinary Medical Association — https://www.avma.org
• American Animal Hospital Association — https://www.aaha.org
• DEA Diversion Control Division (controlled-substance requirements) — https://www.deadiversion.usdoj.gov
• IDEXX Laboratories (Cornerstone, Neo) — https://www.idexx.com
• ezyVet cloud veterinary practice management — https://www.ezyvet.com
• DVM360 veterinary news and software coverage — https://www.dvm360.com
• Today's Veterinary Practice — https://todaysveterinarypractice.com
• North American Veterinary Community / VMX — https://navc.com
• Covetrus veterinary technology and supply — https://www.covetrus.com
• Mars Veterinary Health (Banfield, BluePearl, VCA) — https://www.marsveterinary.com

Related on PULSE

• [GTM Playbook for Veterinary Clinics in 2027](/knowledge/gp0272)
• [GTM Playbook for Acupuncture Clinics in 2027](/knowledge/gp0345)
• [GTM Playbook for Physical Therapy Clinics in 2027](/knowledge/gp0320)
• [How do you build a vertical SaaS for general contractors (Procore competitor space) go-to-market motion in 2027?](/knowledge/gp0088)
• [How do you build a vertical SaaS for electrical contractors go-to-market motion in 2027?](/knowledge/gp0087)
• [How do you build a vertical SaaS for roofing contractors go-to-market motion in 2027?](/knowledge/gp0086)